Publications by authors named "Sarah Batson"

Background: Respiratory and bulbar dysfunctions (including swallowing, feeding, and speech functions) are key symptoms of spinal muscular atrophy (SMA), especially in its most severe forms. Demonstrating the long-term efficacy of disease-modifying therapies (DMTs) necessitates an understanding of SMA natural history.

Objective: This study summarizes published natural history data on respiratory, swallowing, feeding, and speech functions in patients with SMA not receiving DMTs.

View Article and Find Full Text PDF
Article Synopsis
  • In 2020, atezolizumab-bevacizumab became the new standard treatment for first-line unresectable hepatocellular carcinoma (HCC), replacing sorafenib after a decade of use.
  • The systematic literature review (SLR) and network meta-analysis (NMA) aimed to compare the effectiveness of atezolizumab-bevacizumab against other approved treatments for unresectable HCC.
  • The analysis of 49 studies indicated that atezolizumab-bevacizumab likely offers better overall survival compared to most other treatments, although some results were inconclusive.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on spinal muscular atrophy (SMA), a progressive neuromuscular disorder that leads to motor function loss and associated complications like scoliosis and contractures, aiming to understand its natural progression and treatment outcomes.
  • The research reviewed 93 publications analyzing motor function, scoliosis, and contracture outcomes in SMA patients, particularly focusing on types 1-3, and included data from various study designs.
  • Findings indicate that significant loss of motor function is expected across all ages in SMA patients, highlighting the long-term risks for untreated individuals, especially those with types 2 and 3 SMA.
View Article and Find Full Text PDF

Purpose: Semaglutide has demonstrated safe and effective weight loss for overweight and obesity, including participants with concomitant type 2 diabetes mellitus (T2DM), in randomized placebo-controlled trials (RCTs). We conducted a systematic literature review (SLR) and network meta-analyses (NMA) to compare weekly semaglutide 2.4 mg with pharmacological comparators for weight management in overweight or obesity.

View Article and Find Full Text PDF

Vagus nerve stimulation (VNS) Therapy® is an adjunctive neurostimulation treatment for people with drug-resistant epilepsy (DRE) who are unwilling to undergo resective surgery, have had unsuccessful surgery or are unsuitable for surgery. A systematic review and meta-analysis were conducted to determine the treatment effects of VNS Therapy as an adjunct to anti-seizure medications (ASMs) for the management of adults with DRE. A literature search was performed in August 2020 of the Medline®, Medline® Epub Ahead of Print, Embase, and the Cochrane library databases.

View Article and Find Full Text PDF

To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by real-world evidence. Systematic review and meta-analysis of observational studies including patients with NVAF on apixaban and rivaroxaban, which reported stroke/systemic embolism and/or major bleeding. Prospero registration number: CRD42021251719.

View Article and Find Full Text PDF

Objectives: The current systematic review (SR) was undertaken to summarise the published literature reporting the clinical and economic value of automation for chemotherapy preparation management to include compounding workflow software and robotic compounding systems.

Methods: Literature searches were conducted in MEDLINE, Embase and the Cochrane Library on 16 November 2017 to identify publications investigating chemotherapy compounding workflow software solutions used in a hospital pharmacy for the preparation of chemotherapy.

Results: 5175 publications were screened by title and abstract and 18 of 72 full publications screened were included.

View Article and Find Full Text PDF

Objectives: The current systematic review (SR) was undertaken to identify and summarise the published literature reporting on the clinical and economic value of automated in-hospital pharmacy services with a primary focus on systems supporting the dispensing of medicines.

Methods: Literature searches were conducted in MEDLINE, Embase and the Cochrane Library on 17 December 2017 to identify English-language publications investigating any automated dispensing systems (ADSs) in the inpatient setting to include central pharmacy and ward-based systems.

Results: 4320 publications were screened by title and abstract and 45 of 175 full publications screened were included.

View Article and Find Full Text PDF

To conduct a systematic review and meta-analysis feasibility of clinical, quality of life and economic evidence for neurotrophic tropomyosin-related receptor tyrosine kinases () inhibitors in patients with gene fusion-positive tumors. Databases were searched for studies on inhibitors in adult and pediatric patients. 27 publications reported clinical data for seven interventions.

View Article and Find Full Text PDF

D-cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes: alanine racemase and D-alanine:D-alanine ligase. By a combination of structural, chemical and mechanistic studies here we show that the inhibition of D-alanine:D-alanine ligase by the antibiotic D-cycloserine proceeds via a distinct phosphorylated form of the drug. This mechanistic insight reveals a bimodal mechanism of action for a single antibiotic on different enzyme targets and has significance for the design of future inhibitor molecules based on this chemical structure.

View Article and Find Full Text PDF

Introduction: The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung cancer (NSCLC) with + mutations. However, most patients develop resistance, with the result that median progression-free survival (PFS) iŝ12 months. Combining EGFR-TKIs with other agents, such as bevacizumab, is a promising approach to prolonging remission.

View Article and Find Full Text PDF

Objectives: The aim of the study was to develop the three-dimensional (3D) evidence network plot system-a novel web-based interactive 3D tool to facilitate the visualization and exploration of covariate distributions and imbalances across evidence networks for network meta-analysis (NMA).

Study Design And Setting: We developed the 3D evidence network plot system within an AngularJS environment using a third party JavaScript library (Three.js) to create the 3D element of the application.

View Article and Find Full Text PDF

Aims: Meta-analysis is of critical importance to decision makers to assess the comparative efficacy and safety of interventions and is integral to health technology assessment. A major problem for the meta-analysis of continuous outcomes is that associated variance data are not consistently reported in trial publications. The omission of studies from a meta-analysis due to incomplete reporting may introduce bias.

View Article and Find Full Text PDF

Background: Patients with atrial fibrillation are at a greater risk of stroke and therefore the main goal for treatment of patients with atrial fibrillation is to prevent stroke from occurring. There are a number of different stroke prevention treatments available to include warfarin and novel oral anticoagulants. Previous network meta-analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation acknowledge the limitation of heterogeneity across the included trials but have not explored the impact of potentially important treatment modifying covariates.

View Article and Find Full Text PDF

Background: Meta-analysis is a growing approach to evidence synthesis and network meta-analysis in particular represents an important and developing method within Health Technology Assessment (HTA). Meta-analysis of survival data is usually performed using the individual summary statistic-the hazard ratio (HR) from each randomised controlled trial (RCT).

Objectives: The objectives of this study are to: (i) review the methods and reporting of survival analyses in oncology RCTs; and (ii) assess the suitability and relevance of survival data reported in RCTs for inclusion into meta-analysis.

View Article and Find Full Text PDF

Background: We conducted a review of randomized trials to compare the overall survival (OS) with fulvestrant 500 mg versus alternative treatment for estrogen receptor-positive advanced breast cancer following endocrine therapy failure.

Materials And Methods: Hazard ratios (HRs) were obtained by modeling OS data with the Weibull distribution. A fixed-effect Bayesian network meta-analysis was conducted.

View Article and Find Full Text PDF
Article Synopsis
  • - Stroke is a major risk associated with atrial fibrillation, and non-vitamin K antagonist oral anticoagulants (NOACs) like apixaban, dabigatran, rivaroxaban, and edoxaban are effective for preventing strokes in patients with certain risk scores.
  • - A comprehensive analysis of over 70,000 patients showed that apixaban has lower risks of stroke and major bleeding compared to other NOACs and warfarin, making it a strong choice for stroke prevention.
  • - In specific patient groups defined by their CHADS2 score and previous stroke history, apixaban maintained its superior safety and efficacy, though some treatment comparisons were less significant due to smaller subgroup sizes. *
View Article and Find Full Text PDF

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for patients with chronic-phase CML, and its introduction was associated with substantial improvements in response and survival compared with previous therapies. Clinical trial data are now available for the second-generation TKIs (nilotinib, dasatinib, and bosutinib) in the first-, second-, and third-line settings.

View Article and Find Full Text PDF

A recombinant form of Escherichia coli DdlB (EcDdlB) has been prepared and cocrystallized with ADP and D-alanyl-D-alanine to represent the ternary complex of EcDdlB. Furthermore, EcDdlB has been cocrystallized under the same conditions with the ligands ATP and D-alanyl-D-alanine, representing the product-inhibited complex. The crystals belonged to space group P2(1)2(1)2(1), with unit-cell parameters a = 53.

View Article and Find Full Text PDF

The Van enzymes are ATP-dependant ligases responsible for resistance to vancomycin in Staphylococcus aureus and Enteroccoccus species. The de novo molecular design programme SPROUT was used in conjunction with the X-ray crystal structure of Enterococcus faeciumd-alanyl-d-lactate ligase (VanA) to design new putative inhibitors based on a hydroxyethylamine template. The two best ranked structures were selected and efficient syntheses developed.

View Article and Find Full Text PDF